Drug Profile
Vamorolone - Santhera Pharmaceuticals
Alternative Names: AGAMREE; VB-15; VBP-15Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator ReveraGen BioPharma
- Developer ReveraGen BioPharma; Santhera Pharmaceuticals
- Class Anti-inflammatories; Antianaemics; Antiasthmatics; Antifibrotics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duchenne muscular dystrophy
- Preclinical Unspecified
- Discontinued Amyotrophic lateral sclerosis; Asthma; Brain cancer; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia; Spinal muscular atrophy
Most Recent Events
- 13 Mar 2024 Launched for Duchenne muscular dystrophy (In adolescents, In children, In the elderly, In adults) in USA (PO)
- 14 Feb 2024 Efficacy data from a phase IIb VISION-DMD trial for Duchenne muscular dystrophy released by Santhera Pharmaceuticals
- 15 Jan 2024 Launched for Duchenne muscular dystrophy (In adults, In children, In adolescents, In the elderly) in Germany (PO)